Charles River Labs to Discuss Fourth-Quarter Demand Trends at Evercore Conference

Details

announced via Regulation FD Disclosure that it will present at the Evercore 8th Annual Healthcare Conference. During the presentation, management intends to provide updates on fourth-quarter demand trends, specifically focusing on Discovery and Safety Assessment (DSA) booking activity and related key performance indicators, noting positive momentum since mid-fiscal 2025.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.